After seven years of debate, and 19 formal rounds of negotiations, the Trans-Pacific Partnership was agreed in October this year. Its IP provisions, which are among the most controversial, will have an impact on pharmaceutical protection, copyright, trade marks, geographical indications and enforcement, among other areas. Peter Leung provides a summary of the main points and over the following pages we look at the impact country-by-country
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
Abbott winning another round against Sinocare and Menarini, and 'long arm' clarification on the UK's position within the UPC, were also among major developments
Executive chair Matt Dixon, who reveals a new associate hire, says the firm wants to offer a realistic pathway to partnership while avoiding the ‘corporate machine’ route
Kevin Mack, Via’s new president, emphasises the importance of collaborative licensing structures and shares how AI tools can help create new lines of business